Public data, as of October 2026

Company profile

Colonis Pharma Limited

colonis.co.ukNo disclosure matched yet

The Data Hub has no reported emissions for this company yet, so there is no footprint to summarize.

Is this your company? Claim it

SBTi statusCommitment to Set Targets

Near-term status: Commitment to Set Targets. Net-zero status: Commitment to Set Targets.

Where insetting fits

Scope 3 appears once a full disclosure is matched.

Peer position

A peer comparison appears once sector peers report their emissions.

Voluntary retirements

No voluntary retirement names this company as beneficiary yet.

Emissions

How the reported footprint breaks down by scope and year.

tCO₂e, GHG Protocol scopes

Peer benchmark

How Colonis Pharma Limited compares with its industry peers on Scope 3.

Peers: companies in the SBTi industry "Pharmaceuticals, Biotechnology and Life Sciences", by Scope 3 share of the latest reported footprint.

CompanyScope 3 share%

Colonis Pharma LimitedThis companyScope 3 share
McKesson Corporation99%

Company profile

A claimed profile keeps the figures accurate and shows the company’s projects.

Claiming is free. Your team can correct data, add newer disclosures and list reduction projects from your value chain, so that customers and suppliers can co-fund them.

Claim this profile Talk to Carbon3

1
Confirm employment at the company

Related projects

None yet

Inset projects on Carbon3None yet

Reported emissions by year

Scope 1
Scope 2
Scope 3

No reported emissions for this company yet

Carbon3 compiles emissions from published sustainability reports and normalizes them to the GHG Protocol scopes. This company has not been covered yet, or has not published figures that could be read reliably.

Scope 3 categories are not itemized yet

Categories appear once a published disclosure splits Scope 3 into the GHG Protocol categories.

Climate targets

What the SBTi listing says about the company's targets.

Status as published by the SBTi

Primary SBTi record: Colonis

Near-term targetCommitment to Set Targets

Classification: Not listed
Target year: Not listed

Net-zero targetCommitment to Set Targets

Net-zero year: Not listed

Carbon3 shows each record exactly as the SBTi publishes it, and does not assess, rate or endorse targets. A validated target says nothing about any market instrument.

Voluntary retirements

Voluntary credits retired for this company on public registries.

Registry records naming the company as beneficiary

No voluntary credit retirements linked to this company

Carbon3 has not found a retirement in the public voluntary carbon market registry data it tracks that names this company as the beneficiary.

Bayer Aktiengesellschaft

74%

Thermo Fisher Scientific Inc.94%

Merck & Co., Inc.87%

AstraZeneca plc98%

Merck KGaA81%

Peer median: 91%Scope 3 boundaries differ between reports, so compare shares with care.

Scope 3 position

No peer median yet

The median appears when at least one peer reports all three scopes.

Disclosure coverage

6 of 6 disclose

6 of 6 named peers report all three scopes, so their Scope 3 share can be compared.

Research summary

What the public record says about this company's decarbonization.

No report has been generated for this company yet

Anyone can read a cached company report, while generating a new one can take a few minutes and needs a free account.

Related projects

Decarbonization projects that name the company as a partner.

Emerging projects catalog, status as reported by each project

No projects linked to this company yet

Carbon3 has not yet found a public decarbonization project that names this company.

No inset projects are listed for this company yet.

Suppliers to Colonis Pharma Limited can list a reduction project on Carbon3 at no cost, so that the company could co-fund it.

List a supplier project

Sign in with an email address at the company's own domain.

2

Review the data

Flag corrections and upload newer disclosures, which Carbon3 checks against a published source.

3

List a project at no cost

Turn verified supply-chain reductions into inset credits that partners can co-fund.

A free account also gives access to downloads, alerts and new research reports.